<DOC>
	<DOCNO>NCT00422955</DOCNO>
	<brief_summary>Fluid management study patient type 2 diabetes autonomic neuropathy .</brief_summary>
	<brief_title>Fluid Retention Rosiglitazone Treated Subjects With Autonomic Neuropathy .</brief_title>
	<detailed_description />
	<mesh_term>Peripheral Nervous System Diseases</mesh_term>
	<mesh_term>Nervous System Diseases</mesh_term>
	<mesh_term>Diabetic Neuropathies</mesh_term>
	<mesh_term>Rosiglitazone</mesh_term>
	<criteria>Inclusion criterion : Subjects Type 2 Diabetes ( T2DM ) define 1999 WHO criteria [ World Health Organisation , 1988/NCD/NCS/99.2 ] stable FPG = 7.0 = 15.0 mmol/l establish insulin therapy least 6 month BMI = 40 kg.m2 Subject willing able provide sign dated write informed consent . Subjects HbA1c level &gt; 12 % Subjects take oral hypoglycaemic agent metformin Subjects insulin dosage &gt; 200 units/day</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>fluid retention</keyword>
	<keyword>Autonomic Neuropathy</keyword>
</DOC>